LILRA5
Leukocyte immunoglobulin-like receptor subfamily A member 5
Also known as: CD85, CD85f, ILT11, LILRB7, LIR9, LIRA5_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- A6NI73
- Gene
- LILRA5
- Ensembl
- ENSG00000187116
- Chromosome
- 19
- Canonical length
- 299 aa
- Protein class
- CD markers, Predicted membrane proteins, Predicted secreted proteins
- Secretome location
- Secreted to blood
OverviewNCBI Gene
The protein encoded by this gene is a member of the leukocyte immunoglobulin-like receptor (LIR) family. LIR family members are known to have activating and inibitory functions in leukocytes. Crosslink of this receptor protein on the surface of monocytes has been shown to induce calcium flux and secretion of several proinflammatory cytokines, which suggests the roles of this protein in triggering innate immune responses. This gene is one of the leukocyte receptor genes that form a gene cluster on the chromosomal region 19q13.4. Four alternatively spliced transcript variants encoding distinct isoforms have been described. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
299 residues, UniProt reviewed canonical sequence.
>A6NI73|LILRA5
1 MAPWSHPSAQ LQPVGGDAVS PALMVLLCLG LSLGPRTHVQ AGNLSKATLW AEPGSVISRG
61 NSVTIRCQGT LEAQEYRLVK EGSPEPWDTQ NPLEPKNKAR FSIPSMTEHH AGRYRCYYYS
121 PAGWSEPSDP LELVVTGFYN KPTLSALPSP VVTSGENVTL QCGSRLRFDR FILTEEGDHK
181 LSWTLDSQLT PSGQFQALFP VGPVTPSHRW MLRCYGSRRH ILQVWSEPSD LLEIPVSGAA
241 DNLSPSQNKS DSGTASHLQD YAVENLIRMG MAGLILVVLG ILIFQDWHSQ RSPQAAAGRLocalizationUniProt · AlphaFold · HPA
Whether an antibody against LILRA5 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.41
- Highest tissue expression
- 73 nTPM
Expression across tissuesHPA
Tissue
- spleen: 73 nTPM
- bone marrow: 41 nTPM
- appendix: 34 nTPM
- lung: 21 nTPM
- urinary bladder: 15 nTPM
- adipose tissue: 7.5 nTPM
Single-cell type
- neutrophils: 23 nCPM
- monocytes: 12 nCPM
- neutrophil progenitors: 3.7 nCPM
- platelets: 2.8 nCPM
- macrophages: 1.5 nCPM
- monocyte progenitors: 1.4 nCPM
Immune cell
- non-classical monocyte: 313 nTPM
- intermediate monocyte: 253 nTPM
- neutrophil: 138 nTPM
- classical monocyte: 129 nTPM
- total PBMC: 65 nTPM
- myeloid DC: 39 nTPM
Brain region
- cerebral cortex: 1.8 nTPM
- choroid plexus: 1.1 nTPM
- medulla oblongata: 1.1 nTPM
- pons: 1 nTPM
- thalamus: 0.8 nTPM
- white matter: 0.8 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.49
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.15
- DepMap mean gene effect
- 0.02
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cytokine-mediated signaling pathway
- immune response-regulating signaling pathway
- innate immune response
- negative regulation of interleukin-12 production
- negative regulation of interleukin-13 production
- positive regulation of calcium ion transport
- positive regulation of cell activation
- positive regulation of inflammatory response
- positive regulation of interleukin-1 beta production
- positive regulation of interleukin-10 production
- positive regulation of interleukin-6 production
- positive regulation of MAPK cascade
- positive regulation of protein tyrosine kinase activity
- positive regulation of tumor necrosis factor production
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LILRA5 as an antibody target. Whether an autoantibody or antibody against LILRA5 could matter depends on whether native LILRA5 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LILRA5 is annotated at the cell surface, where native LILRA5 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label LILRA5 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...